Clinical, biological and liver histological characteristics of patients according to NAFLD stage
| NAFLD Stage . | All Patients . | Healthy . | NAFL . | NASH . | NASH-F . | P-value . |
|---|---|---|---|---|---|---|
| n | 112 | 23 | 30 | 30 | 29 | |
| Sex (women/men) | 59/53 | 15/8 | 15/15 | 15/15 | 14/15 | 0.61 |
| Age (years) | 42.6 ± 12.5 | 40 ± 12 | 43 ± 11 | 43 ± 13 | 43 ± 13 | 0.75 |
| BMI (kg/m2) | 40.5 ± 6.5 | 38 ± 4.9 | 42 ± 6.5 | 39 ± 4.5 | 41 ± 5.7 | 0.11 |
| Fasting plasma glucose (mg/dL) | 86 ± 10 | 85 ± 9.9 | 86 ± 13.6 | 87 ± 11.9 | 89 ± 8.8 | 0.23 |
| HbA1c (%) | 5.6 ± 0.5 | 5.4 ± 0.3 | 5.6 ± 0.4 | 5.6 ± 0.4 | 5.5 ± 0.6 | 0.32 |
| HOMA-IR | 4.1 ± 2.8 | 4.2 ± 4.7 | 3.5 ± 1.8 | 4.0 ± 2.4 | 4.3 ± 1.5 | 0.32 |
| HOMA2-B (%) | 181 ± 69 | 177 ± 65 | 186 ± 80 | 185 ± 73 | 174 ± 58 | 0.82 |
| HOMA2-S (%) | 57 ± 36 | 64 ± 46 | 48 ± 24 | 58 ± 28 | 60 ± 37 | 0.95 |
| HOMA2-IR | 2.3 ± 1.4 | 1.9 ± 0.9 | 2.8 ± 2 | 2.3 ± 1.2 | 2.1 ± 0.8 | 0.64 |
| Steatosis grade (0,1,2,3) | 23/39/25/25 | 23/0/0/0 | 0/22/8/0 | 0/12/6/12 | 0/5/11/13 | <0.0001 |
| Ballooning (0,1,2) | 43/46/23 | 23/0/0 | 20/7/3 | 0/18/12 | 0/21/8 | <0.0001 |
| Lobular inflammation (0,1,2,3) | 41/44/21/6 | 23/0/0/0 | 18/10/2/0 | 0/20/8/2 | 0/14/11/4 | <0.0001 |
| Fibrosis stage (0,1,2,3,4) | 69/12/23/8/0 | 23/0/0/0/0 | 26/2/2/0/0 | 20/10/0/0/0 | 0/0/21/8/0 | <0.0001 |
| NAFLD Stage . | All Patients . | Healthy . | NAFL . | NASH . | NASH-F . | P-value . |
|---|---|---|---|---|---|---|
| n | 112 | 23 | 30 | 30 | 29 | |
| Sex (women/men) | 59/53 | 15/8 | 15/15 | 15/15 | 14/15 | 0.61 |
| Age (years) | 42.6 ± 12.5 | 40 ± 12 | 43 ± 11 | 43 ± 13 | 43 ± 13 | 0.75 |
| BMI (kg/m2) | 40.5 ± 6.5 | 38 ± 4.9 | 42 ± 6.5 | 39 ± 4.5 | 41 ± 5.7 | 0.11 |
| Fasting plasma glucose (mg/dL) | 86 ± 10 | 85 ± 9.9 | 86 ± 13.6 | 87 ± 11.9 | 89 ± 8.8 | 0.23 |
| HbA1c (%) | 5.6 ± 0.5 | 5.4 ± 0.3 | 5.6 ± 0.4 | 5.6 ± 0.4 | 5.5 ± 0.6 | 0.32 |
| HOMA-IR | 4.1 ± 2.8 | 4.2 ± 4.7 | 3.5 ± 1.8 | 4.0 ± 2.4 | 4.3 ± 1.5 | 0.32 |
| HOMA2-B (%) | 181 ± 69 | 177 ± 65 | 186 ± 80 | 185 ± 73 | 174 ± 58 | 0.82 |
| HOMA2-S (%) | 57 ± 36 | 64 ± 46 | 48 ± 24 | 58 ± 28 | 60 ± 37 | 0.95 |
| HOMA2-IR | 2.3 ± 1.4 | 1.9 ± 0.9 | 2.8 ± 2 | 2.3 ± 1.2 | 2.1 ± 0.8 | 0.64 |
| Steatosis grade (0,1,2,3) | 23/39/25/25 | 23/0/0/0 | 0/22/8/0 | 0/12/6/12 | 0/5/11/13 | <0.0001 |
| Ballooning (0,1,2) | 43/46/23 | 23/0/0 | 20/7/3 | 0/18/12 | 0/21/8 | <0.0001 |
| Lobular inflammation (0,1,2,3) | 41/44/21/6 | 23/0/0/0 | 18/10/2/0 | 0/20/8/2 | 0/14/11/4 | <0.0001 |
| Fibrosis stage (0,1,2,3,4) | 69/12/23/8/0 | 23/0/0/0/0 | 26/2/2/0/0 | 20/10/0/0/0 | 0/0/21/8/0 | <0.0001 |
Data are expressed as mean ± standard deviation. P-values are obtained using the Chi-square test for qualitative data and the analysis of variance test for quantitative data. P-values < 0.05 are considered statistically significant (bold).
Clinical, biological and liver histological characteristics of patients according to NAFLD stage
| NAFLD Stage . | All Patients . | Healthy . | NAFL . | NASH . | NASH-F . | P-value . |
|---|---|---|---|---|---|---|
| n | 112 | 23 | 30 | 30 | 29 | |
| Sex (women/men) | 59/53 | 15/8 | 15/15 | 15/15 | 14/15 | 0.61 |
| Age (years) | 42.6 ± 12.5 | 40 ± 12 | 43 ± 11 | 43 ± 13 | 43 ± 13 | 0.75 |
| BMI (kg/m2) | 40.5 ± 6.5 | 38 ± 4.9 | 42 ± 6.5 | 39 ± 4.5 | 41 ± 5.7 | 0.11 |
| Fasting plasma glucose (mg/dL) | 86 ± 10 | 85 ± 9.9 | 86 ± 13.6 | 87 ± 11.9 | 89 ± 8.8 | 0.23 |
| HbA1c (%) | 5.6 ± 0.5 | 5.4 ± 0.3 | 5.6 ± 0.4 | 5.6 ± 0.4 | 5.5 ± 0.6 | 0.32 |
| HOMA-IR | 4.1 ± 2.8 | 4.2 ± 4.7 | 3.5 ± 1.8 | 4.0 ± 2.4 | 4.3 ± 1.5 | 0.32 |
| HOMA2-B (%) | 181 ± 69 | 177 ± 65 | 186 ± 80 | 185 ± 73 | 174 ± 58 | 0.82 |
| HOMA2-S (%) | 57 ± 36 | 64 ± 46 | 48 ± 24 | 58 ± 28 | 60 ± 37 | 0.95 |
| HOMA2-IR | 2.3 ± 1.4 | 1.9 ± 0.9 | 2.8 ± 2 | 2.3 ± 1.2 | 2.1 ± 0.8 | 0.64 |
| Steatosis grade (0,1,2,3) | 23/39/25/25 | 23/0/0/0 | 0/22/8/0 | 0/12/6/12 | 0/5/11/13 | <0.0001 |
| Ballooning (0,1,2) | 43/46/23 | 23/0/0 | 20/7/3 | 0/18/12 | 0/21/8 | <0.0001 |
| Lobular inflammation (0,1,2,3) | 41/44/21/6 | 23/0/0/0 | 18/10/2/0 | 0/20/8/2 | 0/14/11/4 | <0.0001 |
| Fibrosis stage (0,1,2,3,4) | 69/12/23/8/0 | 23/0/0/0/0 | 26/2/2/0/0 | 20/10/0/0/0 | 0/0/21/8/0 | <0.0001 |
| NAFLD Stage . | All Patients . | Healthy . | NAFL . | NASH . | NASH-F . | P-value . |
|---|---|---|---|---|---|---|
| n | 112 | 23 | 30 | 30 | 29 | |
| Sex (women/men) | 59/53 | 15/8 | 15/15 | 15/15 | 14/15 | 0.61 |
| Age (years) | 42.6 ± 12.5 | 40 ± 12 | 43 ± 11 | 43 ± 13 | 43 ± 13 | 0.75 |
| BMI (kg/m2) | 40.5 ± 6.5 | 38 ± 4.9 | 42 ± 6.5 | 39 ± 4.5 | 41 ± 5.7 | 0.11 |
| Fasting plasma glucose (mg/dL) | 86 ± 10 | 85 ± 9.9 | 86 ± 13.6 | 87 ± 11.9 | 89 ± 8.8 | 0.23 |
| HbA1c (%) | 5.6 ± 0.5 | 5.4 ± 0.3 | 5.6 ± 0.4 | 5.6 ± 0.4 | 5.5 ± 0.6 | 0.32 |
| HOMA-IR | 4.1 ± 2.8 | 4.2 ± 4.7 | 3.5 ± 1.8 | 4.0 ± 2.4 | 4.3 ± 1.5 | 0.32 |
| HOMA2-B (%) | 181 ± 69 | 177 ± 65 | 186 ± 80 | 185 ± 73 | 174 ± 58 | 0.82 |
| HOMA2-S (%) | 57 ± 36 | 64 ± 46 | 48 ± 24 | 58 ± 28 | 60 ± 37 | 0.95 |
| HOMA2-IR | 2.3 ± 1.4 | 1.9 ± 0.9 | 2.8 ± 2 | 2.3 ± 1.2 | 2.1 ± 0.8 | 0.64 |
| Steatosis grade (0,1,2,3) | 23/39/25/25 | 23/0/0/0 | 0/22/8/0 | 0/12/6/12 | 0/5/11/13 | <0.0001 |
| Ballooning (0,1,2) | 43/46/23 | 23/0/0 | 20/7/3 | 0/18/12 | 0/21/8 | <0.0001 |
| Lobular inflammation (0,1,2,3) | 41/44/21/6 | 23/0/0/0 | 18/10/2/0 | 0/20/8/2 | 0/14/11/4 | <0.0001 |
| Fibrosis stage (0,1,2,3,4) | 69/12/23/8/0 | 23/0/0/0/0 | 26/2/2/0/0 | 20/10/0/0/0 | 0/0/21/8/0 | <0.0001 |
Data are expressed as mean ± standard deviation. P-values are obtained using the Chi-square test for qualitative data and the analysis of variance test for quantitative data. P-values < 0.05 are considered statistically significant (bold).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
